# Study Finds No Benefit of Psychedelic Therapy Over Antidepressants > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/psychedelic-therapy-study-no-benefit-over-antidepressants/ > **Published:** 2026-03-19T17:31:04-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:58:02-04:00 > **Clinical Summary:** This psychedelic therapy study reveals no significant benefit over antidepressants, highlighting the need for careful mental health treatment evaluation. --- ✦ New CED Clinical Relevance #55 Clinical Context Background information relevant to the evolving [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) landscape. Mental HealthResearchSafety Clinical Summary This study examined psychiatric comorbidity patterns in young people with [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) compared to those with other substance use disorders, finding that cannabis users demonstrated elevated rates of psychiatric diagnoses relative to their peers with alternative substance dependencies. The findings suggest that cannabis use disorder in adolescents and young adults may be particularly associated with concurrent mental health conditions, which has significant implications for screening and integrated treatment approaches in clinical practice. Clinicians managing patients with cannabis use disorder should maintain heightened awareness of potential underlying or co-occurring psychiatric conditions and consider comprehensive mental health assessment as standard of care in this population. These results underscore the importance of not attributing all psychiatric symptoms solely to cannabis use, as the high comorbidity rates indicate genuine independent mental health needs requiring targeted intervention. Understanding this pattern helps clinicians develop more effective treatment plans that address both substance use and mental health simultaneously rather than sequentially. Practitioners should implement routine psychiatric screening in young patients presenting with cannabis use disorder to identify and manage comorbid conditions that may influence treatment outcomes and prognosis. Dr. Caplan’s Take “What we’re seeing in this data is that young people with cannabis use disorder aren’t presenting with depression because cannabis treats it, but rather they’re self-medicating an underlying psychiatric condition that requires proper diagnosis and evidence-based treatment, and we’re doing them a disservice if we normalize cannabis as a substitute for the structured care they actually need.” Clinical Perspective While this study highlights elevated psychiatric comorbidity in young people with cannabis use disorder compared to those with other substance dependencies, clinicians should recognize that the direction and nature of these associations remain complex and potentially bidirectional. The finding that cannabis users show higher rates of psychiatric diagnoses could reflect cannabis as a risk factor, self-medication of underlying conditions, or diagnostic bias in how symptoms are assessed and attributed. Given the evolving neurobiology of [adolescent brain development](https://cedclinic.com/adolescent-cb1-receptor-antagonism-social-behavior/) and the heterogeneity of cannabis products now available (varying THC/CBD ratios, potency, and routes of administration), a single diagnosis of “cannabis use disorder” may obscure meaningful subgroups with different psychiatric trajectories. In clinical practice, this underscores the importance of conducting thorough psychiatric screening in all young people presenting with cannabis use, while remaining thoughtful about whether psychiatric symptoms precede, coincide with, or follow cannabis initiation. Treating the comorb 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Psychedelic+therapy+shows+no+benefit+over+antidepressants%3A+Study+%40drcaplan&url=https%3A%2F%2Fwww.beckersbehavioralhealth.com%2Fresearch-analysis%2Fpsychedelic-therapy-shows-no-benefit-over-antidepressants-study%2F)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.beckersbehavioralhealth.com%2Fresearch-analysis%2Fpsychedelic-therapy-shows-no-benefit-over-antidepressants-study%2F)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Psychedelic+therapy+shows+no+benefit+over+antidepressants%3A+Study+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fwww.beckersbehavioralhealth.com%2Fresearch-analysis%2Fpsychedelic-therapy-shows-no-benefit-over-antidepressants-study%2F)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) Related Articles - [Psychedelics may be no better than antidepressants for depression: studies – ABC News](https://cedclinic.com/psychedelics-depression-comparative-studies/) 📰 Source: [https://www.beckersbehavioralhealth.com/research-analysis/psychedelic-therapy-shows-no-benefit-over-antidepressants-study/](https://www.beckersbehavioralhealth.com/research-analysis/psychedelic-therapy-shows-no-benefit-over-antidepressants-study/) Further Reading Evidence Watch[`Cannabinoid Clinical Trials: CBD vs Placebo in Fibromyalgia`](https://cedclinic.com/cbd-for-fibromyalgia-clinical-trial-evidence/) Research Digest[Research Digest: 20 Recent Studies – March 18, 2026](https://cedclinic.com/research-digest-recent-studies-march-2026/) CED Clinic Blog[3 Key Findings: Cannabis Alzheimer’s Treatment Study 2025](https://cedclinic.com/cannabis-alzheimer-treatment-research-2025/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [420 with CNW — Study Links Psychiatric Disorders to Adolescent Cannabis Use](https://cedclinic.com/adolescent-cannabis-psychiatric-outcomes-2026-digest/) Explore research linking [adolescent cannabis use](https://cedclinic.com/adolescent-cannabis-use-and-anxiety-research/) with psychiatric disorders, providing context for mental health considerations. [Read More](https://cedclinic.com/adolescent-cannabis-psychiatric-outcomes-2026-digest/) [Endocannabinoid System Research: Teen Cannabis & Mental Health](https://cedclinic.com/endocannabinoid-system-adolescent-psychiatric-risk/) Understand how the [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) impacts teen cannabis use and mental health outcomes. [Discover Insights](https://cedclinic.com/endocannabinoid-system-adolescent-psychiatric-risk/) [Cannabis caution as study finds increased psychosis risk for young people](https://cedclinic.com/cannabis-caution-as-study-finds-increased-psychosis-risk-for-young-people/) Review findings on the increased psychosis risk linked to cannabis use among youth, emphasizing clinical caution. [Learn More](https://cedclinic.com/cannabis-caution-as-study-finds-increased-psychosis-risk-for-young-people/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).